Africa’s first-ever Phase 1 trial of a long-acting injectable for malaria prevention launches in Rwanda
Medicines for Malaria Venture (MMV) and Rinda Ubuzima, a leading Rwandan health research organization, today announced the launch of a
Full story
Read the full story at Business Day ↗
Continue reading this story on Business Day, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
